Alzheimer's Disease Trial, By Invitation NCT05477862 Sponsor: Northwestern University Condition: Alzheimer's Disease
Back to Alzheimers Disease

Alzheimer's Disease Trial, By Invitation

NCT05477862
By Invitation Not Applicable

voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice

Who may and may not be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who may be able to join

  • People who are cognitively healthy (no memory or thinking problems).
  • Cognitively healthy people evaluated through the Northwestern Mesulam Center who have a Beck Anxiety Index (BAI) score greater than 8 (a measure suggesting at least a mild level of anxiety) (confirm with trial site).

Who may not be able to join

Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.

  • People who have hearing loss.
  • People who have mild to moderate Alzheimer's disease.
  • People recruited through the Mesulam Center who have mild to moderate memory or thinking problems caused by Alzheimer's disease, with specific test scores indicating the severity of their condition, a history of agitation or anxiety related to their condition, and an anxiety score above a certain threshold (confirm with trial site for exact score requirements).
  • People whose cognitive test scores fall below a certain level or whose dementia rating is above a certain level, or who have hearing loss (confirm with trial site for exact score thresholds).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 17 August 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
By Invitation
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
1 September 2023
Est. completion
15 December 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Change in Neuropsychiatric Inventory (NPI) [NPI-1: pre-intervention; NPI-2: post-intervention]; Change in Beck Anxiety Inventory [BAI-1: pre-intervention; BAI-2: post-intervention]

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 17 August 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov